American Cancer Society Journals

🧬 "The mechanism is the next big question." In our latest #CancerSpeak podcast, Dr. Koichi Takahashi discusses findings from Dr. Pinkal Desai’s paper on clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) in solid tumor risk. He highlights how these findings could guide future research into organ- and genotype-specific risks and mechanisms. Listen to the full episode: https://lnkd.in/e5ndc7BD And read Dr. Takahashi's accompanying editorial to Dr. Desai's paper: https://lnkd.in/eh7TBHQN OncoAlert

In case you missed it: The weekly OncoAlert newsletter is out and features new research published in CANCER highlighting global disparities in cancer care. Read the full article co-authored by CANCER Editor-in-Chief Emeritus Fadlo R. Khuri, MD here: https://lnkd.in/e75dFcnU

New in Cancer 📗 Desmoid tumors (DTs) are rare and locally invasive tumors which have biologically heterogeneous behavior. Although a DT is not life-threatening in the majority of cases, patients often suffer from chronic pain, functional deficits, psychological problems, and a decrease in quality of life. Despite its often unpredictable clinical course, DT remains understudied, with very few prospectively conducted phase 3 trials. As such, efforts to harmonize treatment and bring together a consensus guideline in the management of this disease continue. In this context, consider the original work below from Yale School of Medicine Oncology fellow Dr. Philippos Costa and colleagues. Their multi-institutional, retrospective analysis illustrates the comparative efficacy and safety of sorafenib and anthracycline-based chemotherapies in treating patients with DT. https://lnkd.in/eBWpcZ2f Findings also emphasize that among patients with DT, sorafenib- and anthracycline-based therapeutic outcomes are optimized via personalized treatment planning and tumor characteristic considerations. Dr. Bernd Kasper, Professor in the Interdisciplinary Tumor Center at Mannheim University Medical Center in Germany, offers further insights on this article and area of research in an accompanying editorial. https://lnkd.in/eQf7GkZT

🎙️ New #CancerSpeak Podcast Episode! https://lnkd.in/e5ndc7BD Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are changing how we understand cancer risk. In our latest episode, CANCER Section Editor and Host Dr. Courtney DiNardo of MD Anderson Cancer Center discusses exciting new findings with: ➡️ Dr. Pinkal Desai of Weill Cornell Medicine, lead author of a recent study in CANCER ➡️ Dr. Koichi Takahashi and Ms. Nehali Shah, co-authors of the study's accompanying editorial, both from MD Anderson Cancer Center Together, they unpack how CHIP and mCAs relate to solid tumor incidence and mortality, with a focus on breast, lung, and colorectal cancer. Listen to the full episode: https://lnkd.in/e5ndc7BD

American Society of Clinical Oncology guideline update on palliative care for patients with cancer: Addressing the reality gap Commentary on Cancer by ACS The American Society of Clinical Oncology's recommendations for integrating palliative care into oncology are commendable but face significant practical challenges, including workforce shortages, limited resources, and insufficient financial support for necessary research. While these guidelines provide an aspirational framework, their full implementation may be unattainable for many programs. Practical strategies for adopting these recommendations at cancer centers are proposed, emphasizing the need for financial and quality incentives to drive the broader integration of palliative care into the healthcare system. Fionnuala Crowley Cardinale B. Smith, MD, PhD American Cancer Society Journals https://buff.ly/3AQh6vG

📗 New study published in CANCER uncovers significant disparities in cancer care between high- and low-income countries, driven by inequities in drug costs, healthcare infrastructure, and access to newer therapies: https://lnkd.in/e75dFcnU The analysis, which drew on relevant published studies and reviews related to cancer and the availability of cancer treatments, predicts that there will be an estimated 28.4 million new cancer cases worldwide in 2040 alone. In the coming years, cancer incidence is expected to increase most significantly in low-income countries. Cancer mortality rates are also increasing in low-income countries, whereas they have leveled off in developed countries. “Cancer incidence and mortality are on the rise globally and are expected to disproportionately affect people in low- and middle-income countries. Unfortunately, access to newer cancer therapeutics is far more restricted in low- and middle-income countries due to prohibitive costs,” said senior author Fadlo R. Khuri, MD, of the American University of Beirut Medical Center, in Lebanon. “In this paper, we analyze the data and propose a few solutions that could help alleviate these worsening disparities—including the use of quality generics and biosimilars and the implementation of universal healthcare coverage and international medical funding.” Access the full study, coauthored by Arafat H. Tfayli MD and Laura El-halabi MD: https://lnkd.in/e75dFcnU #CancerCare #GlobalHealth #HealthEquity

Remember—it's #LungCancerAwarenessMonth 🫁 Take time to further explore the recently published and growing series of manuscripts constituting the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) strategic plan. The principal objective of the NLCRT is to diminish the impact of lung cancer through risk reduction, early detection, and equitable access to high-quality care. #OpenAccess and available now in CANCER: https://lnkd.in/g7e_2meT #LCAM #LungCancer #LungCancerScreening #CancerResearch #HealthEquity

❓ What role does social media play in bridging the gap for those who cannot attend meetings like #ESMO24 in person? In our latest CancerSpeak episode, CANCER Social Media Editor Dr. Gil Morgan discusses how OncoAlert helps amplify important findings from major oncology meetings like the ESMO Annual Congress and fosters a rich exchange of diverse perspectives among cancer health care professionals and patient advocates. Tune in to hear more from Dr. Morgan and other highlights from #ESMO24. Listen here: https://lnkd.in/eiwK7HES #CancerSpeak #ClinicalOncology #CancerCare #PatientAdvocacy

🎙️ 📗 In our latest CancerSpeak episode, Jason Luke MD discusses recent progress in #melanoma treatment highlighted at #ESMO24 and explains how immunotherapy and early-stage interventions are shifting melanoma care. Tune in to hear Dr. Luke’s insights and learn how next-generation developments could shape clinical practice: https://lnkd.in/eiwK7HES OncoAlert #CancerSpeak #MelanomaResearch #ClinicalOncology #Immunotherapy #CancerCare

🚨 🎙️ New Podcast Episode Alert! In a special edition of CancerSpeak, we break down highlights from ESMO 2024 with insights from our Editor-in-Chief Suresh S. Ramalingam, MD, CANCER Social Media Editor Gil Morgan MD, CANCER Melanoma and Skin Section Editor Jason Luke MD, and Deborah Collyar, founder of Patient Advocates in Research (PAIR). Deborah shares the patient perspective on new melanoma and immunotherapy advances presented by Dr. Luke at #ESMO24, emphasizing the need for accessible communication to help patients understand how these findings affect them. Watch her clip below and listen to the full episode for more key takeaways from one of the most influential oncology meetings of the year. https://lnkd.in/eiwK7HES OncoAlert #CancerSpeak #PatientAdvocacy #ClinicalOncology